Good Tolerance Of Lenalidomide Maintenance Therapy In Patients With High Risk Profile Chronic Lymphocytic Leukemia (Cll) After Frontline Chemoimmunotherapy: Preliminary Safety Overview Of The Cllm1 Trial Of The German Cll Study Group (Gcllsg)

Introduction: CLL patients (pts) with persistence of minimal residual disease (MRD) after frontline chemoimmunotherapy or an unfavourable genetic profile have a high risk of early relapse and a short survival (Fink et al., Leukemia 2013). Therefore, the GCLLSG designed the CLLM1 trial, a phase 3, randomized, double-blinded, placebo-controlled study to investigate the efficacy and safety of lenalidomide maintenance therapy for high–risk (HR) CLL following first-line chemoimmunotherapy. HR is defined by the presence of MRD at levels of ≥10-2 or the combination of MRD levels of ≥10-4 to <10-2 with an unmutated IGHV status, or del(17p) or TP53 mutations.